Unlike neutropenia, which has established management with G-CSF, CIT is often undertreated. This leads to chemotherapy dose reductions that can worsen patient outcomes. Newer TPO receptor agonists are effective, but the problem itself remains an underappreciated gap in oncology practice.
Contrary to common assumptions, standard initial steroid therapy is ineffective for the vast majority of adult ITP patients. Approximately 80% progress to chronic disease, highlighting the urgent need for more effective first- and second-line therapies to alter the disease course.
In the VahIT-three trial, heavily pre-treated ITP patients achieved a 44% response rate with just four infusions of unalumab. This offers a significant advantage over chronic daily therapies, providing a short treatment course with the potential for durable response in a difficult-to-treat population.
While used for ITP, rituximab (a CD20 antibody) actually increases levels of BAF, a cytokine that promotes B-cell growth. This is counterproductive. In contrast, newer agents like unalumab block the BAF receptor, offering a more direct and potentially superior mechanism of action.
Platelet aggregation studies show riluzobrutinib does not impair platelet function. This unique profile suggests it may not need to be stopped before surgery, avoiding the risk of a perilous drop in platelet counts for ITP patients—a key differentiator from other BTK inhibitors.